Trial Profile
A Single Center, Non-randomized, Open Phase II Clinical Study of Albumin-bound Paclitaxel Plus Nedaplatin in Patients With Advanced, Recurrent Metastatic Cervical Cancer
Status:
Recruiting
Phase of Trial:
Phase II
Latest Information Update: 27 Sep 2023
Price :
$35
*
At a glance
- Drugs Nedaplatin (Primary) ; Paclitaxel (Primary)
- Indications Cervical cancer
- Focus Therapeutic Use
- Acronyms CSAPPPCC
- 03 Oct 2016 Results (n=27) of a efficacy and safety analysis published in the Cancer.
- 24 Aug 2012 New trial record